https://www.zacks.com/stock/news/2194945/why-is-sage-therapeutics-inc-sage-up-12-7-since-last-earnings-report?cid=CS-ZC-FT-realtime_blog-2194945
Dec 07, 2023 - Sage Therapeutics, Inc. (SAGE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
zc:-6255742797797165468
0
https://www.zacks.com/stock/news/2227293/ionis-ions-olezarsen-gets-fda-s-orphan-tag-for-rare-disease?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2227293
Feb 16, 2024 - FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year.
zc:-4389715286765519151
0
https://www.zacks.com/stock/news/2195115/pharvaris-phvs-stock-up-18-on-hae-drug-meeting-study-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195115
Dec 07, 2023 - Data from a mid-stage study shows that treatment with Pharvaris' (PHVS) investigational HAE drug reduced the monthly attack rate by 84.5%.
zc:-1589640119503404161
0
https://www.zacks.com/stock/news/2200063/ionis-ions-out-licenses-europe-rights-for-hae-drug-to-otsuka?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200063
Dec 19, 2023 - Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.
zc:930078806051963455
0
https://www.zacks.com/stock/news/2201507/pharma-stock-roundup-fda-nod-to-azn-s-eplontersen-crl-to-mrk-s-cough-candidate?cid=CS-ZC-FT-analyst_blog|stock_roundup-2201507
Dec 22, 2023 - FDA approves AstraZeneca (AZN) and Ionis' (IONS) Wainua (eplontersen) for ATTRv-PN and gives CRL to Merck's chronic cough candidate, gefapixant.
zc:-7526906717007563212
0
https://www.zacks.com/stock/news/2214493/ionis-ions-donidalorsen-meets-late-stage-hae-study-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2214493
Jan 23, 2024 - Ionis (IONS) reports positive phase III study results, which show that treatment with donidalorsen achieved a statistically significant reduction in HAE attacks.
zc:1208704822551980256
0
https://www.zacks.com/stock/news/2224200/ionis-ions-eplontersen-gets-fast-track-tag-for-new-indication?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2224200
Feb 09, 2024 - The FDA bestows a Fast Track designation to Ionis (IONS) and partner AstraZeneca's (AZN) eplontersen for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
zc:-8752732866061150146
0
https://www.zacks.com/stock/news/2226254/ionis-pharmaceuticals-ions-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q4-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2226254
Feb 14, 2024 - Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zc:5921006878873404771
0